Riociguat (Adempas)

Indications

CHEST-1 Study of Riociguat in Patients with Inoperable CTEPH/Persistent or Recurrent CTEPH After Pulmonary Thrombendarterectomy (PTE) Surgery (2013) [MEDLINE]
- Riociguat Improved Exercise Capacity (6-Minute Walk Test)
- Riociguat Improved Pulmonary Vascular Resistance (PVR)
- Riociguat Decreased NT Pro-BNP Levels
- Riociguat Improved WHO Functional Class
Use of Riociguat as a Bridge to PTE Surgery Has Not Been Studied

PATENT-1 Study of Riociguat in Symptomatic Pulmonary Hypertension (2013) [MEDLINE]
- Riociguat Improved Exercise Capacity (6-Minute Walk Test)
- Riociguat Improved Pulmonary Vascular Resistance (PVR)
- Riociguat Decreased NT Pro-BNP Levels
- Riociguat Improved WHO Functional Class
- Riociguat Improved Time to Clinical Worsening
- Riociguat Improved Borg Dyspnea Score

Pulmonary Vasodilator
- Directly Stimulates Soluble Guanylate Cyclase (sGC)
- Sensitizes sGC to NO

Right Ventricular Failure (see xxxx, [[xxxx]]): although occurred in the same percentage of patients (3%) in both placebo and riociguat groups [MEDLINE]
Syncope (see Syncope, [[Syncope]]): occurred in 2% of riociguat group vs 3% of placebo group [MEDLINE]

Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Heart J 2009;30:2493-2537 [MEDLINE]
Riociguat for chronic thomboembolic pulmonary hypertension and pulmonary arterial hypertension: a phase II study. Eur Respir J 2010;36:792-799 [MEDLINE]
CHEST-1 Study Group. Riociguat for the treatment of chronic thromboembolic pulmonary hypertension. N Engl J Med. 2013 Jul 25;369(4):319-29. doi: 10.1056/NEJMoa1209657 [MEDLINE]
PATENT-1 Study Group. Riociguat for the treatment of pulmonary arterial hypertension. N Engl J Med. 2013 Jul 25;369(4):330-40. doi: 10.1056/NEJMoa1209655 [MEDLINE]
Riociguat for pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension. Am J Health Syst Pharm. 2014 Nov 1;71(21):1839-44. doi: 10.2146/ajhp130777 [MEDLINE]